733
edits
Cardiac Pharmacology: Difference between revisions
no edit summary
No edit summary |
|||
| Line 621: | Line 621: | ||
|- | |- | ||
|rowspan="3"|PCSK9 Inhibitors | |rowspan="3"|PCSK9 Inhibitors | ||
|Evolocumab, Alirocumab | |Evolocumab, Alirocumab, Inclisiran | ||
|Primary hypercholesterolemia, Mixed Dyslipidemia, Homozygous Familial Hypercholesterolemia | |Primary hypercholesterolemia, Mixed Dyslipidemia, Homozygous Familial Hypercholesterolemia | ||
|Evolocumab: 140mg every 2 weeks or 420mg once monthly | |Evolocumab: 140mg every 2 weeks or 420mg once monthly | ||
Alirocumab: 75mg to 150mg every 2 weeks | Alirocumab: 75mg to 150mg every 2 weeks | ||
Inclisiran dosages according to specific treatment regimes | |||
|Primary hypercholesterolemia and Mixed Dyslipidemia: Class I; Homozygous Familial Hypercholesterolemia: Class I <cite>Esc2</cite> <cite>Esc3</cite> | |Primary hypercholesterolemia and Mixed Dyslipidemia: Class I; Homozygous Familial Hypercholesterolemia: Class I <cite>Esc2</cite> <cite>Esc3</cite> | ||
|Injection site reactions (5.9%), nasopharyngitis (5.5%), upper respiratory tract infections (2.3%), flu (3.1%), back pain (3.2%), hypersensitivity reactions including rash, pruritus (1.7%), and rare cases of neurocognitive effects such as memory loss or confusion. | |Injection site reactions (5.9%), nasopharyngitis (5.5%), upper respiratory tract infections (2.3%), flu (3.1%), back pain (3.2%), hypersensitivity reactions including rash, pruritus (1.7%), and rare cases of neurocognitive effects such as memory loss or confusion. | ||